Bradley A McGregor, MD
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bradley A McGregor, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:26 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04724018 · Sacituzumab Govitecan Plus EV in Metastatic UCDana-Farber Cancer Institute · recruiting · Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter · principal investigator
- Ph2NCT04040725 · Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 OverexpressionDana-Farber Cancer Institute · withdrawn · Bladder Cancer · principal investigator
- Ph2NCT03333616 · Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsDana-Farber Cancer Institute · active not recruiting · Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 11:26 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed
- 363 citationsRCR 18.1